Amgen Inc (AMGN) 138.69 $AMGN
Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014
M2 - 1 hr 5 mins ago
Research and Markets (http://www.researchandmarkets.com/research/gr3rvm/global_peptide) has announced the addition of the "Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014" report to their offering. The conventional methods developed to prevent and eradicate the prevalence of cancer have achieved limited success in cancer treatment. These methods are confined to low specificity, safety and large number of side effects, which prompted the researchers to look for a better solution. It has been discovered that peptides can be used for effective and viable treatment of cancer without having disadvantages of conventional methods. The quintessential for using peptide cancer therapeutics is that they have high specificity, safety and efficacy which is not provide by therapeutics available in market. The completion of human genome sequencing has helped in the research and development of peptide cancer therapeutics. The data allowed the researchers to look deep into the root cause of cancer hidden in human genome. This has allowed targeting cancer cells with high accuracy; thus, increasing the probability of treatment with high success rates. Using this data several novel molecules are being developed, which will have higher stability, effective delivery and minimal or no side-effects. Peptide cancer therapeutics has edge in treating rare type of cancers. Conventional approaches of cancer treatments are unable to treat them successfully. Sometimes these approaches cannot be used due to unspecificity or they are not effective at all. For instance, brain cancer is a rare type of cancer that falls in this category. Key Topics Covered: 1. Introduction to Peptide Cancer Therapeutics 2. Mechanism of Peptide Cancer Therapeutics 3. Peptide Cancer Therapeutics Market Outlook 4. Peptide Cancer Therapeutics Market Dynamics 5. Peptide Cancer Therapeutics Market Future Growth Prospects 6. Peptide Cancer Drug Clinical Pipeline by Phase, Indication, Company & Country 7. Marketed Peptide Cancer Drug Insight by Indication, Country & Company 8. Suspended & Discontinued Peptide Cancer Drug in Clinical Trial by Phase, Indication, Company & Country 9. Competitive Landscape Companies Mentioned: - AngioChem - Antigen Express - Amgen - GlaxoSmithKline - Galena Biopharma - Ipsen - Merck - PeptiDream - Roche - Sanofi For more information visit http://www.researchandmarkets.com/research/gr...al_peptide
Amgen edges up on trial results
at Investor's Business Daily - Thu Aug 28, 5:42PM CDT
The biotech firm edged up 0.6% to 138.69 after reporting positive results from its phase three trial of evolocumab in combination with statins in Japanese patients. Amgen's (AMGN) evolocumab is an injectable cholesterol fighter for patients whose...
Amgen's Chronic Heart Failure Drug Gets Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 5:20PM CDT
Amgen Inc. (AMGN) received encouraging news from the FDA as the regulatory body granted priority review status to the New Drug Application (NDA) for its pipeline candidate, ivabradine.
Final Glance: Biotechnology companies
AP - Thu Aug 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Aegerion Resolves FDA's Warning on Juxtapid, Lifts Overhang - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 4:50PM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) has resolved the issues mentioned in the FDA's warnings letter on the marketing and sales of Juxtapid in the U.S.
MediciNova Rises on FDA's Nod on MN-166 Study Initiation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 4:00PM CDT
MediciNova's (MNOV) shares have gained 7.7% ever since the company announced that it will be starting a clinical study on MN-166.
BioTime's AST-OPC1 Cleared by FDA for Phase I/IIa Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:35PM CDT
BioTime, Inc. (BTX) announced that the FDA has granted permission to its subsidiary, Asterias Biotherapeutics, Inc., for a phase I/IIa study on AST-OPC1.
Repros Reports Encouraging Late-Stage Data on Androxal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:30PM CDT
Repros Therapeutics Inc. (RPRX) announced positive top-line data on its secondary hypogonadism candidate, Androxal, from a pivotal phase III study.
Midday Glance: Biotechnology companies
AP - Thu Aug 28, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
3 Health Care Stocks Pushing The Sector Higher
at The Street - Thu Aug 28, 12:04PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Acquisitions, Appointment, and Vaccine Recommendations - Research Reports on InterMune, Amgen, Johnson & Johnson, Merck and Medtronic
PR Newswire - Thu Aug 28, 8:30AM CDT
Today, Analysts Review released its research reports regarding InterMune Inc. (NASDAQ: ITMN), Amgen, Inc. (NASDAQ: AMGN), Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK) and Medtronic, Inc. (NYSE: MDT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6042-100free.
Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol
PR Newswire - Thu Aug 28, 8:15AM CDT
Amgen (NASDAQ:AMGN) today announced that the Phase 3 YUKAWA-2 (StudY of LDL-Cholesterol Reduction Using a Monoclonal PCSK9 Antibody in Japanese Patients With Advanced Cardiovascular Risk) study evaluating evolocumab in combination with statin therapy in Japanese patients with high cardiovascular risk and high cholesterol met its co-primary endpoints: the percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week 12 and the mean percent reduction from baseline in LDL-C at weeks 10 and 12. The percent reduction in LDL-C, or "bad" cholesterol, was clinically meaningful, statistically significant, and consistent with the results observed for the same doses in the Phase 2 YUKAWA trial for evolocumab compared to placebo.1
Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA
PR Newswire - Thu Aug 28, 8:00AM CDT
Amgen (NASDAQ: AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for evolocumab seeking approval for the treatment of high cholesterol. Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood.1
Why Amgen (AMGN) Stock Hit a One-Year High Today
at The Street - Wed Aug 27, 9:32AM CDT
Amgen (AMGN) hit a 52-week high of $137.99 on Wednesday after the Food and Drug Administration granted priority review for the company's prospective chronic heart failure treatment drug ivabradine.
Early Glance: Biotechnology companies
AP - Wed Aug 27, 9:18AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Amicus Therapeutics Hits 52-Week High on Migalastat Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:49AM CDT
Shares of Amicus Therapeutics (FOLD) hit a 52-week high of $6.28 during the trading session on Aug 26.
FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure
PR Newswire - Wed Aug 27, 8:15AM CDT
Amgen (NASDAQ: AMGN) today announced the U.S. Food and Drug Administration (FDA) has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF). Ivabradine is an oral drug that inhibits the If current ("funny" current) in the sinoatrial node, the body's cardiac pacemaker.1 Ivabradine works to slow the heart rate without negative effects on myocardial contractility or ventricular repolarization.1 Heart failure is a common condition that affects approximately 26 million worldwide, including approximately 5.1 million people in the U.S.2,3
7 Things Regeneron Pharmaceuticals Inc.'s Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Tue Aug 26, 8:56PM CDT
Regeneron Pharmaceuticals held a conference call earlier this month to highlight its second-quarter earnings and give investors some insight into the biotech's prospects for the rest of the year. Here are seven things management wants you to know....
Kite Pharma Drug Fares Well in Non-Hodgkin's Lymphoma Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 5:44PM CDT
Kite Pharma, Inc. (KITE) announced the publication of positive results from an ongoing phase I-IIa study on KTE-C19 for aggressive non-Hodgkin's lymphoma.
Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014
M2 - 1 hr 5 mins ago
Research and Markets (http://www.researchandmarkets.com/research/gr3rvm/global_peptide) has announced the addition of the "Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014" report to their offering. The conventional methods developed to prevent and eradicate the prevalence of cancer have achieved limited success in cancer treatment. These methods are confined to low specificity, safety and large number of side effects, which prompted the researchers to look for a better solution. It has been discovered that peptides can be used for effective and viable treatment of cancer without having disadvantages of conventional methods. The quintessential for using peptide cancer therapeutics is that they have high specificity, safety and efficacy which is not provide by therapeutics available in market. The completion of human genome sequencing has helped in the research and development of peptide cancer therapeutics. The data allowed the researchers to look deep into the root cause of cancer hidden in human genome. This has allowed targeting cancer cells with high accuracy; thus, increasing the probability of treatment with high success rates. Using this data several novel molecules are being developed, which will have higher stability, effective delivery and minimal or no side-effects. Peptide cancer therapeutics has edge in treating rare type of cancers. Conventional approaches of cancer treatments are unable to treat them successfully. Sometimes these approaches cannot be used due to unspecificity or they are not effective at all. For instance, brain cancer is a rare type of cancer that falls in this category. Key Topics Covered: 1. Introduction to Peptide Cancer Therapeutics 2. Mechanism of Peptide Cancer Therapeutics 3. Peptide Cancer Therapeutics Market Outlook 4. Peptide Cancer Therapeutics Market Dynamics 5. Peptide Cancer Therapeutics Market Future Growth Prospects 6. Peptide Cancer Drug Clinical Pipeline by Phase, Indication, Company & Country 7. Marketed Peptide Cancer Drug Insight by Indication, Country & Company 8. Suspended & Discontinued Peptide Cancer Drug in Clinical Trial by Phase, Indication, Company & Country 9. Competitive Landscape Companies Mentioned: - AngioChem - Antigen Express - Amgen - GlaxoSmithKline - Galena Biopharma - Ipsen - Merck - PeptiDream - Roche - Sanofi For more information visit http://www.researchandmarkets.com/research/gr...al_peptide
Amgen edges up on trial results
at Investor's Business Daily - Thu Aug 28, 5:42PM CDT
The biotech firm edged up 0.6% to 138.69 after reporting positive results from its phase three trial of evolocumab in combination with statins in Japanese patients. Amgen's (AMGN) evolocumab is an injectable cholesterol fighter for patients whose...
Amgen's Chronic Heart Failure Drug Gets Priority Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 5:20PM CDT
Amgen Inc. (AMGN) received encouraging news from the FDA as the regulatory body granted priority review status to the New Drug Application (NDA) for its pipeline candidate, ivabradine.
Final Glance: Biotechnology companies
AP - Thu Aug 28, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Aegerion Resolves FDA's Warning on Juxtapid, Lifts Overhang - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 4:50PM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) has resolved the issues mentioned in the FDA's warnings letter on the marketing and sales of Juxtapid in the U.S.
MediciNova Rises on FDA's Nod on MN-166 Study Initiation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 4:00PM CDT
MediciNova's (MNOV) shares have gained 7.7% ever since the company announced that it will be starting a clinical study on MN-166.
BioTime's AST-OPC1 Cleared by FDA for Phase I/IIa Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:35PM CDT
BioTime, Inc. (BTX) announced that the FDA has granted permission to its subsidiary, Asterias Biotherapeutics, Inc., for a phase I/IIa study on AST-OPC1.
Repros Reports Encouraging Late-Stage Data on Androxal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 3:30PM CDT
Repros Therapeutics Inc. (RPRX) announced positive top-line data on its secondary hypogonadism candidate, Androxal, from a pivotal phase III study.
Midday Glance: Biotechnology companies
AP - Thu Aug 28, 12:19PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
3 Health Care Stocks Pushing The Sector Higher
at The Street - Thu Aug 28, 12:04PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.
Acquisitions, Appointment, and Vaccine Recommendations - Research Reports on InterMune, Amgen, Johnson & Johnson, Merck and Medtronic
PR Newswire - Thu Aug 28, 8:30AM CDT
Today, Analysts Review released its research reports regarding InterMune Inc. (NASDAQ: ITMN), Amgen, Inc. (NASDAQ: AMGN), Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK) and Medtronic, Inc. (NYSE: MDT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6042-100free.
Amgen Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolocumab In Combination With Statins In Japanese Patients With High Cardiovascular Risk And High Cholesterol
PR Newswire - Thu Aug 28, 8:15AM CDT
Amgen (NASDAQ:AMGN) today announced that the Phase 3 YUKAWA-2 (StudY of LDL-Cholesterol Reduction Using a Monoclonal PCSK9 Antibody in Japanese Patients With Advanced Cardiovascular Risk) study evaluating evolocumab in combination with statin therapy in Japanese patients with high cardiovascular risk and high cholesterol met its co-primary endpoints: the percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week 12 and the mean percent reduction from baseline in LDL-C at weeks 10 and 12. The percent reduction in LDL-C, or "bad" cholesterol, was clinically meaningful, statistically significant, and consistent with the results observed for the same doses in the Phase 2 YUKAWA trial for evolocumab compared to placebo.1
Amgen Submits Biologics License Application For Novel Investigational LDL Cholesterol-Lowering Medication Evolocumab To The FDA
PR Newswire - Thu Aug 28, 8:00AM CDT
Amgen (NASDAQ: AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for evolocumab seeking approval for the treatment of high cholesterol. Evolocumab is an investigational fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood.1
Why Amgen (AMGN) Stock Hit a One-Year High Today
at The Street - Wed Aug 27, 9:32AM CDT
Amgen (AMGN) hit a 52-week high of $137.99 on Wednesday after the Food and Drug Administration granted priority review for the company's prospective chronic heart failure treatment drug ivabradine.
Early Glance: Biotechnology companies
AP - Wed Aug 27, 9:18AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Amicus Therapeutics Hits 52-Week High on Migalastat Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:49AM CDT
Shares of Amicus Therapeutics (FOLD) hit a 52-week high of $6.28 during the trading session on Aug 26.
FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure
PR Newswire - Wed Aug 27, 8:15AM CDT
Amgen (NASDAQ: AMGN) today announced the U.S. Food and Drug Administration (FDA) has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF). Ivabradine is an oral drug that inhibits the If current ("funny" current) in the sinoatrial node, the body's cardiac pacemaker.1 Ivabradine works to slow the heart rate without negative effects on myocardial contractility or ventricular repolarization.1 Heart failure is a common condition that affects approximately 26 million worldwide, including approximately 5.1 million people in the U.S.2,3
7 Things Regeneron Pharmaceuticals Inc.'s Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Tue Aug 26, 8:56PM CDT
Regeneron Pharmaceuticals held a conference call earlier this month to highlight its second-quarter earnings and give investors some insight into the biotech's prospects for the rest of the year. Here are seven things management wants you to know....
Kite Pharma Drug Fares Well in Non-Hodgkin's Lymphoma Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 5:44PM CDT
Kite Pharma, Inc. (KITE) announced the publication of positive results from an ongoing phase I-IIa study on KTE-C19 for aggressive non-Hodgkin's lymphoma.
